Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.
Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:
Boss Energy Ltd (ASX: BOE)
According to a note out of Ord Minnett, its analysts have retained their buy rating and $6.00 price target on this uranium producer's shares. This follows news that asset management company Sprott has announced the purchase of US$200 million in physical uranium for its Sprott Physical Uranium Trust. The broker sees this as a bullish signal for uranium and notes that spot prices have surged this week to US$76 per pound in response. However, these gains could only be getting started, with Ord Minnett believing that the spot U3O8 price will continue to rise to US$90 per pound in 2026. This is being supported partly by the adoption of nuclear power, particularly to fuel the artificial intelligence boom. The Boss Energy share price is trading at $4.62 this afternoon.
CSL Ltd (ASX: CSL)
A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $303.00 price target on this biotherapeutics company's shares. The broker highlights that CSL has received US FDA approval for its Andembry therapy, which aims to help prevent attacks of hereditary angioedema (HAE). While it was pleased with the news, its approval was already expected and factored in by Morgan Stanley. Outside this, the broker sees scope for CSL to boost its earnings per share growth rate through a combination of lower costs and share buybacks. Though, regardless of this, it's base case earnings per share forecast is for low-teen annual growth through to FY 2028. The CSL share price is fetching $240.45 at the time of writing.
Neuren Pharmaceuticals Ltd (ASX: NEU)
Analysts at Macquarie have initiated coverage on this pharmaceuticals company's shares with an outperform rating and an $18.60 price target. According to the note, the broker believes that Neuren offers a rare, asymmetric risk-reward profile. It notes that the company's strategic partnership with Acadia (NASDAQ: ACAD), which covers all commercialisation costs for DAYBUE, allows it to reap 10% to 15% royalty and significant milestone payments with minimal expenses. In addition, Macquarie points out that there's an imminent opportunity for DAYBUE to expand across the world, and its pipeline product, NNZ-2591, has the potential to address multiple neurodegenerative conditions. The Neuren share price is trading at $13.10 on Wednesday.
